Tucidinostat

From WikiMD's WELLNESSPEDIA

Tucidinostat


Tucidinostat (also known as Chidamide) is a histone deacetylase inhibitor (HDACi) used in the treatment of various types of cancer. It is particularly noted for its application in the treatment of peripheral T-cell lymphoma (PTCL) and breast cancer. Tucidinostat is an orally bioavailable, selective inhibitor of histone deacetylase (HDAC) subtypes 1, 2, 3, and 10.

Mechanism of Action[edit]

Tucidinostat works by inhibiting the activity of histone deacetylases, which are enzymes involved in the removal of acetyl groups from histone proteins. This inhibition leads to an accumulation of acetylated histones, resulting in a more relaxed chromatin structure and increased transcriptional activity of certain genes. The reactivation of these genes can induce cell cycle arrest, differentiation, and apoptosis in cancer cells.

Clinical Applications[edit]

Peripheral T-cell Lymphoma[edit]

Tucidinostat has been approved for the treatment of peripheral T-cell lymphoma (PTCL) in several countries. PTCL is a group of aggressive non-Hodgkin lymphomas that originate from mature T-cells and natural killer (NK) cells. The drug has shown efficacy in patients who have relapsed or are refractory to conventional chemotherapy.

Breast Cancer[edit]

In addition to its use in PTCL, Tucidinostat is being investigated for its potential in treating breast cancer. Studies have shown that it can enhance the sensitivity of cancer cells to other therapeutic agents, making it a promising candidate for combination therapy.

Side Effects[edit]

Common side effects of Tucidinostat include fatigue, nausea, vomiting, anemia, and thrombocytopenia. Patients undergoing treatment with Tucidinostat require regular monitoring of blood counts and liver function tests.

Research and Development[edit]

Tucidinostat is currently under investigation in various clinical trials for its efficacy and safety in treating other types of cancer, including non-small cell lung cancer (NSCLC) and colorectal cancer. Researchers are also exploring its potential in combination with other therapeutic agents to enhance its anticancer effects.

See Also[edit]

References[edit]

External Links[edit]

Wikimedia Commons logo
Wikimedia Commons has media related to

Tucidinostat

.
Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Tucidinostat&oldid=5831810"